ENLIVEX THERAPEUTICS LTD (ENLV) Stock Income Statement
USA - NASDAQ:ENLV - IL0011319527 - Common Stock
1.065 USD
+0.01 (+0.95%)
1.06 USD
0 (-0.47%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 15.18M | 15.54M | 25.15M | 25.80M | 19.29M | |||
| Research and Development | 10.46M | 10.13M | 18.21M | 17.95M | 12.34M | |||
| Selling, General, and Administrative Expenses | 4.72M | 4.91M | 6.14M | 7.10M | 6.41M | |||
| Operating Income | -15.18M | -15.54M | -25.15M | -25.80M | -19.29M | |||
| Interest Income/Expense | N/A | 887.00K | 341.00K | -5.25M | 5.15M | |||
| Other Income/Expense | N/A | -13.00K | -14.00K | -10.00K | -330.00K | |||
| Non Recurring Items | -180.00K | -352.00K | -4.24M | N/A | N/A | |||
| Income Before Taxes | -13.10M | -15.01M | -29.07M | -31.06M | -14.47M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -13.10M | -15.01M | -29.07M | -31.06M | -14.47M | |||
| EBITDA | -14.81M | -14.99M | -24.32M | -25.02M | -18.74M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.58 | -0.73 | -1.56 | -1.69 | -0.81 | |||
| Non GAAP EPS | -0.58 | -0.73 | -1.56 | -1.69 | N/A | |||
| Statistics | ||||||||
All data in USD